HAND & WRIST
AAOS2017: Triamcinonlone has higher rate of resolution for trigger finger vs dexamethasone
69 patients with trigger finger were randomized to treatment with either triamcinolone injection or dexamethasone injection. Patients were followed up at 6 weeks, 12 weeks, and 6 months for symptom resolution. Repeat injections were offered in cases of persistent or recurrent symptoms. During follow-up, fewer patients of the triamcinolone group required repeat injection compared to the dexamethasone group. At final follow-up, significantly more patients in the triamcinolone group demonstrated symptom resolution and fewer patients required surgery when compared to the dexamethasone group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
